Evaluation for Venous Thromboembolism Risk Factors in Cushing's Syndrome
STEP 1 — Gather Information
Collect: surgical status (undergoing/planned surgery, recent surgery <4-6 weeks ago), history of VTE, current immobilization, active malignancy, estrogen use, obesity (BMI>30), known thrombophilias.
STEP 2 — Rule In / Rule Out
First binary fork: Is the patient undergoing surgery or within 4-6 weeks postop OR has prior VTE, current immobilization, active malignancy, or estrogen use?
- If yes: Proceed to Step 3 for risk stratification.
- If no: Proceed to Step 3 for low-risk classification.
STEP 3 — Classify or Stratify
If perioperative (surgery <4-6 weeks): Classify as Perioperative High Risk.
Else if non-perioperative:
- Classify as High Risk if prior VTE OR current immobilization OR active malignancy OR estrogen use.
- Classify as Low Risk otherwise.
STEP 4 — Decide
If Perioperative High Risk: Recommend perioperative pharmacologic prophylaxis (e.g., LMWH) unless contraindicated.
If High Risk (non-perioperative): Consider extended pharmacologic prophylaxis if hospitalized; otherwise, monitor for VTE signs and advise on early ambulation.
If Low Risk: Routine clinical monitoring; no specific VTE prophylaxis unless hospitalized for other reasons.
Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on D-dimer for VTE diagnosis in CS due to frequent false positives from inflammation. Avoid delaying prophylaxis in high-risk surgical CS patients due to bleeding risk concerns without hematology consultation. Remember that CS itself is a prothrombotic state; do not withhold prophylaxis based on normal coagulation studies.
Concrete Clinical Example
A 45-year-old woman with active Cushing's disease (post-transsphenoidal surgery 2 weeks ago) presents for follow-up. She has no prior VTE, is ambulating well, no malignancy, not on estrogen.
Step 1: Recent surgery <4-6 weeks ago -> yes.
Step 2: Perioperative yes -> proceed to Step 3.
Step 3: Classified as Perioperative High Risk.
Step 4: Recommend perioperative pharmacologic prophylaxis (e.g., enoxaparin 40 mg daily) until full ambulation.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818